Literature DB >> 7970922

Assessment of the ability of young children to use a powder inhaler device (Turbuhaler).

A Goren1, N Noviski, A Avital, C Maayan, E Stahl, S Godfrey, C Springer.   

Abstract

The purpose of the study was to determine the age at which young asthmatic children could master the use of a new powder inhaler device (Turbuhaler). We studied 59 children with asthma between the ages of 3 and 6 years who consecutively attended the asthma clinic of the pediatric department. Efficiency of inhalation and the pharmacological effect of the terbutaline in the inhaler were measured by scores for inhalation technique and clinical response. None of the 3-year-old children used the device efficiently, but 43% of the 4-year-old, 67% of the 5-year-old, and 80% of the 6-year-old children used the inhaler correctly. Although inhaler technique was not perfect in the younger age group, 50% of the 3-year-old children demonstrated clinical improvement of asthma symptoms after inhalation. In the older age groups, 79%, 92%, and 100% of the 4, 5, and 6-year-old children demonstrated clinical improvement of asthma symptoms after inhalation. It is concluded that the new mode of dry powder delivery system (Bricanyl Turbuhaler) can be used in young asthmatic children who are 4 years of age and above.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7970922     DOI: 10.1002/ppul.1950180204

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  11 in total

1.  Inhalation devices.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

Review 2.  Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003.

Authors:  Allan Becker; Catherine Lemière; Denis Bérubé; Louis-Philippe Boulet; Francine M Ducharme; Mark FitzGerald; Thomas Kovesi
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

Review 3.  Treatment of childhood asthma. Options and rationale for inhaled therapy.

Authors:  C V Powell; M L Everard
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

4.  Provider demonstration and assessment of child device technique during pediatric asthma visits.

Authors:  Betsy Sleath; Guadalupe X Ayala; Chris Gillette; Dennis Williams; Stephanie Davis; Gail Tudor; Karin Yeatts; Deidre Washington
Journal:  Pediatrics       Date:  2011-03-28       Impact factor: 7.124

Review 5.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

6.  Efficacy of two educational interventions about inhalation techniques in patients with chronic obstructive pulmonary disease (COPD). TECEPOC: study protocol for a partially randomized controlled trial (preference trial).

Authors:  Francisca Leiva-Fernández; José Leiva-Fernández; Fernando Zubeldia-Santoyo; Antonio García-Ruiz; Daniel Prados-Torres; Pilar Barnestein-Fonseca
Journal:  Trials       Date:  2012-05-21       Impact factor: 2.279

7.  2003 canadian asthma consensus guidelines executive summary.

Authors:  Allan Becker; Catherine Lemière; Denis Bérubé; Louis-Philippe Boulet; Francine Ducharme; Mark Fitzgerald; Thomas Kovesi
Journal:  Allergy Asthma Clin Immunol       Date:  2006-03-15       Impact factor: 3.406

8.  Effect of inhaler design variables on paediatric use of dry powder inhalers.

Authors:  Anne J Lexmond; Tonnis J Kruizinga; Paul Hagedoorn; Bart L Rottier; Henderik W Frijlink; Anne H de Boer
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

9.  Benefit of hospital pharmacy intervention on the current status of dry powder inhaler technique in patients with asthma and COPD: a study from the Central Development Region, Nepal.

Authors:  Ramesh Sharma Poudel; Rano Mal Piryani; Shakti Shrestha; Aastha Prajapati
Journal:  Integr Pharm Res Pract       Date:  2016-12-20

Review 10.  The Diskus: a review of its position among dry powder inhaler devices.

Authors:  H Chrystyn
Journal:  Int J Clin Pract       Date:  2007-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.